Analysis of potential prognostic factors in 111 patients with ovarian cancer

Cancer Letters

Volumn 206, Issue 1, 2004, Pages 97-106

  Hornung, R ^a   Urs, Eppenberger ^b   Serenella, Eppenberger ^b   Edward, Wight ^b   Ursula, Staub ^a   Urs, Haller ^a   Daniel, Fink ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Ovarian cancer; Predictive factors; Prognostic factors

Indexed keywords

CATHEPSIN D; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ISOPROTEIN; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BIOCHEMISTRY; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL CYCLE S PHASE; CLEAR CELL CARCINOMA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOMETRIOID CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CATHEPSIN D; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; S PHASE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY PLASMINOGEN ACTIVATOR;

EID: 1442310963     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2003.10.034     Document Type: Article

References (56)

1. Jemal A., Thomas A., Murray T., Thun M. Cancer statistics 2002. CA Cancer J. Clin. 52:2002;23-47.
2. Runnebaum I.B., Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk. J. Cancer Res. Clin. Oncol. 127:2001;73-79.
3. Harries M., Gore M. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol. 3:2002;529-536.
4. Heintz A.P., Odicino F., Maisonneuve P., Beller U., Benedet J.L., Creasman W.T., et al. Carcinoma of the ovary. J. Epidemiol. Biostat. 6:2001;107-138.
5. Scully R.E. World Health Organization classification and nomenclature of ovarian cancer. Natl Cancer Inst. Monogr. 42:1975;5-7.
6. Mirza A.N., Mirza N.Q., Vlastos G., Singletary S.E. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann. Surg. 235:2002;10-26.
7. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
8. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:1987;177-182.
9. Ligibel J.A., Winer E.P. Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin. Oncol. 29:2002;38-43.
10. Soussi T., Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat. Rev. Cancer. 1:2001;233-240.
11. Ferrandina G., Scambia G., Bardelli F., Benedetti Panici P., Mancuso S., Messori A. Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. Br. J. Cancer. 76:1997;661-666.
12. Harbeck N., Schmitt M., Kates R.E., Kiechle M., Zemzoum I., Janicke F., Thomssen C. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts. Clin. Breast Cancer. 3:2002;196-200.
13. Kuhn W., Pache L., Schmalfeldt B., Dettmar P., Schmitt M., Janicke F., Graeff H. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol. Oncol. 55:1994;401-409.
14. Cooper B.C., Sood A.K., Davis C.S., Ritchie J.M., Sorosky J.I., Anderson B., Buller R.E. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet. Gynecol. 100:2002;59-64.
15. Merkel D.E., McGuire W.L. Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumors. Cancer. 65:1990;1194-1205.
16. Gershenson D.M., Mitchell M.F., Atkinson N., Silva E.G., Burke T.W., Morris M., et al. Age contrasts in patients with advanced epithelial ovarian cancer. The M.D. Anderson Cancer Center experience. Cancer. 71:1993;638-643.
17. Ries L.A. Ovarian cancer. Survival and treatment differences by age. Cancer. 71:1993;524-529.
18. Redman J.R., Petroni G.R., Saigo P.E., Geller N.L., Hakes T.B. Prognostic factors in advanced ovarian carcinoma. J. Clin. Oncol. 4:1986;515-523.
19. Makar A.P., Baekelandt M., Trope C.G., Kristensen G.B. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol. Oncol. 56:1995;175-180.
20. Hoskins W.J., McGuire W.P., Brady M.F., Homesley H.D., Creasman W.T., Berman M., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170:1994;974-979. discussion 979-80.
21. Delgado G., Oram D.H., Petrilli E.S. Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecol. Oncol. 18:1984;293-298.
22. Nagele E., Kurz C., Speiser P., Vavra N., Sevelda P. -CA-125 antigen as a prognostic factor for survival in patients with epithelial ovarian carcinoma of FIGO stage I-preliminary results. Geburtshilfe Frauenheilkd. 56:1996;79-82.
23. Onetto M., Bruzzone M., Conte P.F., Ruvolo M., Conio A., Chiara S., et al. Evaluation of the ovarian cancer antigen. Ca-125, as a tumor marker. Oncology. 46:1989;117-122.
24. Sevelda P., Schemper M., Spona J. CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. Am. J. Obstet. Gynecol. 161:1989;1213-1216.
25. Cruickshank D.J., Fullerton W.T., Klopper A. The clinical significance of pre-operative serum CA 125 in ovarian cancer. Br. J. Obstet. Gynaecol. 94:1987;692-695.
26. Rustin G.J., Gennings J.N., Nelstrop A.E., Covarrubias H., Lambert H.E., Bagshawe K.D. Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group. J. Clin. Oncol. 7:1989;1667-1671.
27. Mogensen O. Prognostic value of CA 125 in advanced ovarian cancer. Gynecol. Oncol. 44:1992;207-212.
28. Panici P.B., Angioli R. Role of lymphadenectomy in ovarian cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 16:2002;529-551.
29. Trope C. Prognostic factors in ovarian cancer. Cancer Treat. Res. 95:1998;287-352.
30. Lund B., Thomsen H.K., Olsen J. Reproducibility of histopathological evaluation in epithelial ovarian carcinoma. Clinical implications. Apmis. 99:1991;353-358.
31. Sugiyama T., Kamura T., Kigawa J., Terakawa N., Kikuchi Y., Kita T., et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 88:2000;2584-2589.
32. Sorbe B., Frankendal B., Veress B. Importance of histologic grading in the prognosis of epithelial ovarian carcinoma. Obstet. Gynecol. 59:1982;576-582.
33. Dembo A.J., Bush R.S., Brown T.C. Clinico-pathological correlates in ovarian cancer. Bull. Cancer. 69:1982;292-297.
34. Amat S., Penault-Llorca F., Cure H., Le Bouedec G., Achard J.L., Van Praagh I., et al. Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int. J. Oncol. 20:2002;791-796.
35. Munstedt K., Steen J., Knauf A.G., Buch T., von Georgi R., Franke F.E. Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer. 89:2000;1783-1791.
36. Langdon S.P., Gabra H., Bartlett J.M., Rabiaz G.J., Hawkins R.A., Tesdale A.L., et al. Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogen. Clin. Cancer Res. 4:1998;2245-2251.
37. Slotman B.J., Nauta J.J., Rao B.R. Survival of patients with ovarian cancer. Apart from stage and grade, tumor progesterone receptor content is a prognostic indicator. Cancer. 66:1990;740-744.
38. Hempling R.E., Piver M.S., Eltabbakh G.H., Recio F.O. Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancer. Am. J. Clin. Oncol. 21:1998;447-451.
39. Rose P.G., Reale F.R., Longcope C., Hunter R.E. Prognostic significance of estrogen and progesterone receptors in epithelial ovarian cancer. Obstet. Gynecol. 76:1990;258-263.
40. Harding M., Cowan S., Hole D., Cassidy L., Kitchener H., Davis J., Leake R. Estrogen and progesterone receptors in ovarian cancer. Cancer. 65:1990;486-491.
41. Berchuck A., Kamel A., Whitaker R., Kerns B., Olt G., Kinney R., et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50:1990;4087-4091.
42. Meden H., Marx D., Rath W., Kuhn W., Hinney B., Schauer A. Overexpression of c-erbB-2 oncogene in primary ovarian cancers: incidence and prognostic significance in 243 patients. Geburtshilfe und Frauenheilkunde. 52:1992;667-673.
43. Fajac A., Benard J., Lhomme C., Rey A., Duvillard P., Rochard F., et al. c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis. Int. J. Cancer. 64:1995;146-151.
44. Tanner B., Kreutz E., Weikel W., Meinert R., Oesch F., Knapstein P.G., Becker R. Prognostic significance of c-erB-2 mRNA in ovarian carcinoma. Gynecol. Oncol. 62:1996;268-277.
45. Medl M., Sevelda P., Czerwenka K., Dobianer K., Hanak H., Hruza C., et al. DNA amplification of HER-2/neu and INT-2 oncogenes in epithelial ovarian cancer. Gynecol. Oncol. 59:1995;321-326.
46. Young S.R., Liu W.H., Brock J.A., Smith S.T. ERBB2 and chromosome 17 centromere studies of ovarian cancer by fluorescence in situ hybridization. Genes Chromosomes Cancer. 16:1996;130-137.
47. Hartmann L.C., Podratz K.C., Keeney G.L., Kamel N.A., Edmonson J.H., Grill J.P., et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J. Clin. Oncol. 12:1994;64-69.
48. Eltabbakh G.H., Belinson J.L., Kennedy A.W., Biscotti C.V., Casey G., Tubbs R.R., Blumenson L.E. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer. 80:1997;892-898.
49. Levesque M.A., Katsaros D., Yu H., Zola P., Sismondi P., Giardina G., Diamandis E.P. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer. 75:1995;1327-1338.
50. Klemi P.-J., Pylkkönen L., Kiilholma P., Kurvinen K., Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer. 76:1995;1201-1208.
51. Marks J.R., Davidoff A.M., Kerns B.J., Humphrey P.A., Pence J.C., Dodge R.K., et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res. 51:1991;2979-2984.
52. Sheridan E., Silcocks P., Smith J., Hancock B.W., Goyns M.H. P53 mutation in a series of epithelial ovarian cancers from the UK, and its prognostic significance. Eur. J. Cancer. 30A:1994;1701-1704.
53. Ferrandina G., Scambia G., Fagotti A., D'Agostino G., Benedetti Panici P., Carbone A., Mancuso S. Immunoradiometric and immunohistochemical analysis of Cathepsin D in ovarian cancer: lack of association with clinical outcome. Br. J. Cancer. 78:1998;1645-1652.
54. Scambia G., Panici P.B., Ferrandina G., Salerno G., D'Agostino G., Distefano M., et al. Clinical significance of cathepsin D in primary ovarian cancer. Eur. J. Cancer. 30A:1994;935-940.
55. van der Burg M.E., Henzen-Logmans S.C., Berns E.M., van Putten W.L., Klijn J.G., Foekens J.A. Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. Int. J. Cancer. 69:1996;475-479.
56. Hoffmann G., Pollow K., Weikel W., Strittmatter H.J., Bach J., Schaffrath M., et al. Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters. Clin. Chem. Lab. Med. 37:1999;47-54.